These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 31269885)

  • 1. Overview of Molecular Mechanisms Involved in Herbal Compounds for Inhibiting Osteoclastogenesis from Macrophage Linage RAW264.7.
    He G; Ma R
    Curr Stem Cell Res Ther; 2020; 15(7):570-578. PubMed ID: 31269885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses osteoclastogenesis through the inhibition of NF-κB and MAPK pathways via GLP-1R.
    Li Z; Li S; Wang N; Xue P; Li Y
    Biomed Pharmacother; 2020 Oct; 130():110523. PubMed ID: 32702632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shikimic Acid Inhibits Osteoclastogenesis in Vivo and in Vitro by Blocking RANK/TRAF6 Association and Suppressing NF-κB and MAPK Signaling Pathways.
    Chen X; Li X; Zhai X; Zhi X; Cao L; Qin L; Su J
    Cell Physiol Biochem; 2018; 51(6):2858-2871. PubMed ID: 30562759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Egg-Derived Tripeptide IRW Attenuates LPS-Induced Osteoclastogenesis in RAW 264.7 Macrophages via Inhibition of Inflammatory Responses and NF-κB/MAPK Activation.
    Shang N; Wu J
    J Agric Food Chem; 2020 Jun; 68(22):6132-6141. PubMed ID: 32383875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diallyl disulfide alleviates inflammatory osteolysis by suppressing osteoclastogenesis
    Yang J; Tang R; Yi J; Chen Y; Li X; Yu T; Fei J
    FASEB J; 2019 Jun; 33(6):7261-7273. PubMed ID: 30857415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docosahexaenoic acid signaling attenuates the proliferation and differentiation of bone marrow-derived osteoclast precursors and promotes apoptosis in mature osteoclasts.
    Kim HJ; Ohk B; Yoon HJ; Kang WY; Seong SJ; Kim SY; Yoon YR
    Cell Signal; 2017 Jan; 29():226-232. PubMed ID: 27836739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
    Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
    Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Puerarin alleviates osteoporosis in the ovariectomy-induced mice by suppressing osteoclastogenesis via inhibition of TRAF6/ROS-dependent MAPK/NF-κB signaling pathways.
    Xiao L; Zhong M; Huang Y; Zhu J; Tang W; Li D; Shi J; Lu A; Yang H; Geng D; Li H; Wang Z
    Aging (Albany NY); 2020 Nov; 12(21):21706-21729. PubMed ID: 33176281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioactive iron oxide nanoparticles suppress osteoclastogenesis and ovariectomy-induced bone loss through regulating the TRAF6-p62-CYLD signaling complex.
    Liu L; Jin R; Duan J; Yang L; Cai Z; Zhu W; Nie Y; He J; Xia C; Gong Q; Song B; Anderson JM; Ai H
    Acta Biomater; 2020 Feb; 103():281-292. PubMed ID: 31866569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. I‑BET151 inhibits osteoclastogenesis via the RANKL signaling pathway in RAW264.7 macrophages.
    Cheng J; Zheng J; Guo N; Zi F
    Mol Med Rep; 2017 Dec; 16(6):8406-8412. PubMed ID: 28983590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet-derived growth factor BB enhances osteoclast formation and osteoclast precursor cell chemotaxis.
    Li DQ; Wan QL; Pathak JL; Li ZB
    J Bone Miner Metab; 2017 Jul; 35(4):355-365. PubMed ID: 27628046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WSS25, a sulfated polysaccharide, inhibits RANKL-induced mouse osteoclast formation by blocking SMAD/ID1 signaling.
    Chen C; Qin Y; Fang JP; Ni XY; Yao J; Wang HY; Ding K
    Acta Pharmacol Sin; 2015 Sep; 36(9):1053-64. PubMed ID: 26299951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin 29 inhibits RANKL-induced osteoclastogenesis via activation of JNK and STAT, and inhibition of NF-κB and NFATc1.
    Peng Q; Luo A; Zhou Z; Xuan W; Qiu M; Wu Q; Xu L; Kong X; Zhang M; Tan W; Xue M; Wang F
    Cytokine; 2019 Jan; 113():144-154. PubMed ID: 30001863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory Effect of LGS and ODE Isolated from the Twigs of
    Kim GR; Kim EN; Park KJ; Kim KH; Jeong GS
    Molecules; 2021 Mar; 26(6):. PubMed ID: 33810014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diaporisoindole E inhibits RANKL-induced osteoclastogenesis via suppression of PI3K/AKT and MAPK signal pathways.
    Hua P; Cui H; Xu J; Cai R; She Z; Gu Q
    Phytomedicine; 2020 Aug; 75():153234. PubMed ID: 32510335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
    Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
    J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diarylheptanoid Hirsutenone Attenuates Osteoclastogenesis by Suppressing IFNγ and NF-κB Signaling in Th1 and Preosteoclastic Cells.
    Lee DI; Jang SK; Park DW; Kim ST; Park JS; Jo BR; Park JY; Park HY; Joo SS
    Biol Pharm Bull; 2017; 40(5):630-637. PubMed ID: 28458348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Curcumin has immunomodulatory effects on RANKL-stimulated osteoclastogenesis in vitro and titanium nanoparticle-induced bone loss in vivo.
    Yang C; Zhu K; Yuan X; Zhang X; Qian Y; Cheng T
    J Cell Mol Med; 2020 Jan; 24(2):1553-1567. PubMed ID: 31845532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.